Reported Earlier, Vanda Says Phase III HETLIOZ Study Met Primary Endpoint In Delayed Sleep-Wake Phase Disorder, Shifting Sleep Onset 37.1 Minutes Earlier Versus Placebo; sNDA Planned

Loading news article.

Reported Earlier, Vanda Says Phase III HETLIOZ Study Met Primary Endpoint In Delayed Sleep-Wake Phase Disorder, Shifting Sleep Onset 37.1 Minutes Earlier Versus Placebo; sNDA Planned | WAPE

Reported Earlier, Vanda Says Phase III HETLIOZ Study Met Primary Endpoint In Delayed Sleep-Wake Phase Disorder, Shifting Sleep Onset 37.1 Minutes Earlier Versus Placebo; sNDA Planned

Article summary

Related companies

Comments —